RECRUITING

Leniolisib for Immune Dysregulation in CVID

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

In this study, common variable immunodeficiency (CVID) patients will all receive the study drug, leniolisib, for a treatment period of 6 months. Participants will start on a lower dose of leniolisib, followed by a mid and then a higher dose level. The primary goal is to assess the safety and tolerability of leniolisib, and secondary goal is to assess the potential for leniolisib to provide benefits for patients.

Official Title

A Study to Assess Safety and Tolerability, and Explore Efficacy of Leniolisib for Immune Dysregulation in Common Variable Immunodeficiency (CVID)

Quick Facts

Study Start:2025-02-12

Study Completion:2026-10

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06897358

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:12 Years to 75 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:CHILD, ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Subject is 12 to 75 years of age (inclusive). 2. Subject has a clinical diagnosis of CVID supported by: 1. Absent isohemagglutinins and/or poor response to vaccines 2. Low class-switched memory B cells less than 2% AND 3. Low IgA and/or IgM compared to age-adjusted reference range AND 4. No identified secondary causes of hypogammaglobulinemia 3. Inborn Errors of Immunity/ PID Panel testing: 1. Lacks an identified pathogenic/likely pathogenic genetic driver for their CVID primary immunodeficiency OR 2. Subject has an identified pathogenic/likely pathogenic genetic driver(s) for their CVID limited to the following genes: TNFRSF13B (TACI), TNFRSF13C (BAFFR), CD19, CD20, CD81, CR2 (CD21), LRBA, CTLA4, NFKB1, NFKB2, IKZF1 (excluding variants associated with combined immune deficiency), CARD11 (gain of function), SH3KBP1, SEC61A1 IRF2BP2, CTNNBL1, TWEAK or PTEN. 4. Subject has lymphoproliferation, as evidenced by CT imaging: splenomegaly with craniocaudal spleen measurement \>10 cm and/or lymphadenopathy with at least 1 measurable index lymph node (long axis \>1.5 cm) as per Cheson methodology. 5. Subject has at least ONE of the following CVID clinical manifestations of immune dysregulation: 1. Clinical symptoms related to splenomegaly or lymphadenopathy which interfere with activities of daily living or are associated with chronic pain, dyspnea, functional impairment, or limitations in usual activities 2. One or more blood cytopenias related to CVID (and not due to other medical conditions such as iron-deficiency or lead exposure) defined as hemoglobin \<10 g/dL, platelet count \<100,000/µL, and/or neutrophil count \<1,000/µL 3. Previous pathologic confirmation of ILD and attributed to CVID by the Investigator with quantifiable CT chest imaging findings evident on baseline CT scan 4. Clinical diagnosis of CVID enteropathy or other GI tract diagnosis attributable to CVID by the Investigator which involves the small intestine and meets the following enteropathy criteria: 6. At screening, vital signs. Ranges: 7. Subjects or their legal representatives (for subjects under the age of 18 years) must be able to communicate with the Investigator and understand and comply with the requirements of the study, including an ability to provide written informed consent.	1. Laboratory evidence of significant T cell deficiency including CD4+ T cells \<200/uL. 2. Laboratory evidence of significant NK cell deficiency including NK cells \<1% of peripheral blood lymphocytes or less than 50/mcL. 3. Clinical history of infections suggestive of clinically significant T cell or NK cell deficiency such as Pneumocystis jirovecii, atypical mycobacteria, severe warts, or unusually severe (as determined by the PI) infections with herpesviruses. 4. Presence of uncontrolled chronic/recurrent infectious disease (except those considered to be characteristic of antibody deficiency). 5. Positive blood polymerase chain reaction (PCR) for cytomegalovirus or adenovirus. 6. Evidence of tuberculosis infection 7. Positive blood cryptococcal antigen 8. Previous or concurrent use of immunosuppressive medication, such as: * Use of an mTOR inhibitor or a PI3K inhibitor within 3 weeks. * Rituximab or other B cell depleting antibodies, belimumab, cyclophosphamide, or alemtuzumab within 6 months. * Cyclosporine A, mycophenolate mofetil, 6-mercaptopurine, azathioprine, methotrexate, tacrolimus, ruxolitinib, or other Janus kinase (JAK) inhibitors within 3 weeks. * Glucocorticoids above 25 mg prednisone or equivalent per day within 2 weeks * Immunosuppressive monoclonal or polyclonal antibody therapeutics such as directed against TNF-alpha, α₄β₇ integrin, IL-6, IL-12/IL-23 and others within 5 half-lives * Other immunosuppressive agents expected to have a significant impact on immune cell number or function. * Abatacept is allowed during study if the subject has been receiving a stable dosing regimen for more than 3 months . * Enteral budesonide is allowed during study if the subject has been receiving a stable dosing regimen for more than 3 months. 9. Subject is receiving concurrent treatment with another investigational therapy or use of another investigational therapy less than 4 weeks or 5 half-lives (whichever is longer). 10. Current use of medication known to be a strong inhibitor, or moderate or strong inducer, of isoenzyme cytochrome P450 CYP3A. 11. Current use of medications that, to a larger extent, are BCRP, OATP1B1, and/or OATP1B3 substrates. 12. History of HIV or positive test result at screening. 13. Any surgical or medical condition which may jeopardize the subject in case of participation in the study 14. Chronic need for supplemental oxygen or invasive or non-invasive respiratory support 15. Liver failure or clinically significant liver disease or dysfunction as indicated by alanine transaminase (ALT) or aspartate transaminase (AST) greater than 2.5 times the upper limit of normal, bilirubin greater than 2 times the upper limit of normal, international normalized ratio (INR) greater than 1.5 in the absence of anticoagulation, or presence of diuretic refractory ascites. 16. History of significant renal injury/renal disease severely affecting renal function or presence of impaired renal function as indicated by glomerular filtration rate of less than 30 mL/min/1.73 m2. 17. A positive hepatitis B surface antigen (HBsAg), positive hepatitis B PCR, positive hepatitis C PCR, or positive hepatitis C antibody result at screening. 18. Administration of live vaccines starting from 6 weeks before first dose of study medication 19. Subject has a history of malignancy (except lymphoma) within 3 years before the first dose of study medication or has evidence of residual disease from a previously diagnosed malignancy, except for adequately treated cancers of the skin (basal or squamous cell) or carcinoma in situ of the uterine cervix. 20. Subject has a previous diagnosis of lymphoma that has been treated with chemotherapy, radiotherapy, or transplant within 1 year of the first dose of study medication or is anticipated to require lymphoma treatment within 6 months of the first dose of study medication. 21. Subject has uncontrolled post-transplant lymphoproliferative disease-like Epstein-Barr virus related lymphoproliferative disease. 22. Pregnant or nursing (lactating) women. 23. Individuals of child-bearing potential, unless they are using highly effective methods of contraception

Inclusion Criteria

Exclusion Criteria

1. Subject is 12 to 75 years of age (inclusive).
2. Subject has a clinical diagnosis of CVID supported by:
1. Absent isohemagglutinins and/or poor response to vaccines
2. Low class-switched memory B cells less than 2% AND
3. Low IgA and/or IgM compared to age-adjusted reference range AND
4. No identified secondary causes of hypogammaglobulinemia
3. Inborn Errors of Immunity/ PID Panel testing:
1. Lacks an identified pathogenic/likely pathogenic genetic driver for their CVID primary immunodeficiency OR
2. Subject has an identified pathogenic/likely pathogenic genetic driver(s) for their CVID limited to the following genes: TNFRSF13B (TACI), TNFRSF13C (BAFFR), CD19, CD20, CD81, CR2 (CD21), LRBA, CTLA4, NFKB1, NFKB2, IKZF1 (excluding variants associated with combined immune deficiency), CARD11 (gain of function), SH3KBP1, SEC61A1 IRF2BP2, CTNNBL1, TWEAK or PTEN.
4. Subject has lymphoproliferation, as evidenced by CT imaging: splenomegaly with craniocaudal spleen measurement \>10 cm and/or lymphadenopathy with at least 1 measurable index lymph node (long axis \>1.5 cm) as per Cheson methodology.
5. Subject has at least ONE of the following CVID clinical manifestations of immune dysregulation:
1. Clinical symptoms related to splenomegaly or lymphadenopathy which interfere with activities of daily living or are associated with chronic pain, dyspnea, functional impairment, or limitations in usual activities
2. One or more blood cytopenias related to CVID (and not due to other medical conditions such as iron-deficiency or lead exposure) defined as hemoglobin \<10 g/dL, platelet count \<100,000/µL, and/or neutrophil count \<1,000/µL
3. Previous pathologic confirmation of ILD and attributed to CVID by the Investigator with quantifiable CT chest imaging findings evident on baseline CT scan
4. Clinical diagnosis of CVID enteropathy or other GI tract diagnosis attributable to CVID by the Investigator which involves the small intestine and meets the following enteropathy criteria:
6. At screening, vital signs. Ranges:
7. Subjects or their legal representatives (for subjects under the age of 18 years) must be able to communicate with the Investigator and understand and comply with the requirements of the study, including an ability to provide written informed consent.

1. Laboratory evidence of significant T cell deficiency including CD4+ T cells \<200/uL.
2. Laboratory evidence of significant NK cell deficiency including NK cells \<1% of peripheral blood lymphocytes or less than 50/mcL.
3. Clinical history of infections suggestive of clinically significant T cell or NK cell deficiency such as Pneumocystis jirovecii, atypical mycobacteria, severe warts, or unusually severe (as determined by the PI) infections with herpesviruses.
4. Presence of uncontrolled chronic/recurrent infectious disease (except those considered to be characteristic of antibody deficiency).
5. Positive blood polymerase chain reaction (PCR) for cytomegalovirus or adenovirus.
6. Evidence of tuberculosis infection
7. Positive blood cryptococcal antigen
8. Previous or concurrent use of immunosuppressive medication, such as:
* Use of an mTOR inhibitor or a PI3K inhibitor within 3 weeks.
* Rituximab or other B cell depleting antibodies, belimumab, cyclophosphamide, or alemtuzumab within 6 months.
* Cyclosporine A, mycophenolate mofetil, 6-mercaptopurine, azathioprine, methotrexate, tacrolimus, ruxolitinib, or other Janus kinase (JAK) inhibitors within 3 weeks.
* Glucocorticoids above 25 mg prednisone or equivalent per day within 2 weeks
* Immunosuppressive monoclonal or polyclonal antibody therapeutics such as directed against TNF-alpha, α₄β₇ integrin, IL-6, IL-12/IL-23 and others within 5 half-lives
* Other immunosuppressive agents expected to have a significant impact on immune cell number or function.
* Abatacept is allowed during study if the subject has been receiving a stable dosing regimen for more than 3 months .
* Enteral budesonide is allowed during study if the subject has been receiving a stable dosing regimen for more than 3 months.
9. Subject is receiving concurrent treatment with another investigational therapy or use of another investigational therapy less than 4 weeks or 5 half-lives (whichever is longer).
10. Current use of medication known to be a strong inhibitor, or moderate or strong inducer, of isoenzyme cytochrome P450 CYP3A.
11. Current use of medications that, to a larger extent, are BCRP, OATP1B1, and/or OATP1B3 substrates.
12. History of HIV or positive test result at screening.
13. Any surgical or medical condition which may jeopardize the subject in case of participation in the study
14. Chronic need for supplemental oxygen or invasive or non-invasive respiratory support
15. Liver failure or clinically significant liver disease or dysfunction as indicated by alanine transaminase (ALT) or aspartate transaminase (AST) greater than 2.5 times the upper limit of normal, bilirubin greater than 2 times the upper limit of normal, international normalized ratio (INR) greater than 1.5 in the absence of anticoagulation, or presence of diuretic refractory ascites.
16. History of significant renal injury/renal disease severely affecting renal function or presence of impaired renal function as indicated by glomerular filtration rate of less than 30 mL/min/1.73 m2.
17. A positive hepatitis B surface antigen (HBsAg), positive hepatitis B PCR, positive hepatitis C PCR, or positive hepatitis C antibody result at screening.
18. Administration of live vaccines starting from 6 weeks before first dose of study medication
19. Subject has a history of malignancy (except lymphoma) within 3 years before the first dose of study medication or has evidence of residual disease from a previously diagnosed malignancy, except for adequately treated cancers of the skin (basal or squamous cell) or carcinoma in situ of the uterine cervix.
20. Subject has a previous diagnosis of lymphoma that has been treated with chemotherapy, radiotherapy, or transplant within 1 year of the first dose of study medication or is anticipated to require lymphoma treatment within 6 months of the first dose of study medication.
21. Subject has uncontrolled post-transplant lymphoproliferative disease-like Epstein-Barr virus related lymphoproliferative disease.
22. Pregnant or nursing (lactating) women.
23. Individuals of child-bearing potential, unless they are using highly effective methods of contraception

Contacts and Locations

Study Contact

Jason Bradt, MD

CONTACT

+1 908 797 1034

j.bradt@pharming.com

Derrick Carter

CONTACT

+1 619 902 3913

d.carter@pharming.com

Study Locations (Sites)

Lahey Hospital & Medical Center

Burlington, Massachusetts, 01805

United States

Collaborators and Investigators

Sponsor: Pharming Technologies B.V.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-02-12

Study Completion Date2026-10

Study Record Updates

Study Start Date2025-02-12

Study Completion Date2026-10

Terms related to this study

Additional Relevant MeSH Terms

Common Variable Immunodeficiency (CVID)